Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases.

@article{Migliori2008ResistanceTS,
  title={Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases.},
  author={Giovanni Battista Migliori and Christoph Lange and Rosella Centis and Giovanni Sotgiu and Ralf Muetterlein and Hans Hoffmann and Kai Kliiman and Giuseppina De Iaco and Francesco Nicola Lauria and Morgan D'Arcy Richardson and Antonio Spanevello and Daniela M Cirillo},
  journal={The European respiratory journal},
  year={2008},
  volume={31 6},
  pages={1155-9}
}
No information is currently available on the influence of injectable second-line drugs on treatment outcomes of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. To investigate this issue, a large series of MDR- and XDR-TB cases diagnosed in Estonia, Germany, Italy and the Russian Federation (Archangels Oblast) between 1999 and 2006 were analysed. All study sites performed drug susceptibility testing for first- and second-line anti-TB drugs, laboratory… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Antimicrobial agents and chemotherapy • 2012
View 5 Excerpts
Highly Influenced

The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease • 2017

References

Publications referenced by this paper.
Showing 1-10 of 15 references

Impact of extensive

H-R Kim, SS Hwang, HJ Kim
2008

Origin of the term XDR-TB.

The European respiratory journal • 2007

Extensively drug

Africa. Lancet
2006

Similar Papers

Loading similar papers…